The association between geographic access to providers and the treatment quality of pediatric depression.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
15 06 2019
Historique:
received: 19 02 2019
revised: 19 04 2019
accepted: 21 04 2019
pubmed: 30 4 2019
medline: 1 4 2020
entrez: 30 4 2019
Statut: ppublish

Résumé

To examine the association of geographic access to providers with racial/ethnic variations in treatment quality among youth with depression. The geographic access to providers who initiated the depression treatment was measured using the travel distance estimated based on Google Maps® and the provider density within a 5-mile radius of each patient residence. Depression treatment quality was measured as treatment engagement, defined as having ≥2 prescriptions or psychotherapy with 2-month following a new depression diagnosis, and treatment completion defined as having ≥8 sessions of psychotherapy within 12 weeks or received ≥84 days of continuous treatment with antidepressants within 114 days following the treatment initiation. The results of multivariate logistic regression analysis have demonstrated that the travel distance to provider was only negatively associated with the treatment engagement of Hispanics (5.0 - 14.9 vs ≤ 4.9 miles: OR=0.74, 95% CI [0.54-0.88]; ≥15 vs ≤ 4.9 miles: OR=0.82, 95% CI [0.56-0.97]), while a higher mental health specialist density was only positively associated with the treatment engagement of Blacks (1.00-1.99 vs < 1.00: OR=1.63, 95% CI [1.03-4.51]; 2.00-4.99 vs < 1.0: OR=2.28, 95% CI [1.21-7.11]). Among those who have engaged in the treatment, travel distance was associated with a lower likelihood of treatment completion in all racial/ethnic groups. The study did not account for types of transportation used by patients. Geographic access barriers had a negative association with treatment quality of pediatric depression. Minority children were more sensitive to the barriers than Whites.

Identifiants

pubmed: 31035217
pii: S0165-0327(19)30423-9
doi: 10.1016/j.jad.2019.04.091
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

162-170

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Navneet Upadhyay (N)

Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA.

Rajender Aparasu (R)

Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA. Electronic address: rraparasu@uh.edu.

Paul J Rowan (PJ)

Division of Management, Policy, and Community Health, University of Texas School of Public Health, Houston, TX, USA. Electronic address: Paul.J.Rowan@uth.tmc.edu.

Marc L Fleming (ML)

Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA. Electronic address: MLFlemi2@UH.edu.

Rajesh Balkrishnan (R)

University of Virginia School of Medicine, Charlottesville, Virginia, USA. Electronic address: rb9ap@virginia.edu.

Hua Chen (H)

Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, TX, USA. Electronic address: hchen20@uh.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH